The PRIPS study: screening battery for subjects at risk for Parkinson's disease

Abstract

With this approach, one out of 16 positively screened participants developed PD compared to one out of 135 in the original cohort. This corresponds to a sensitivity of 80.0%, a specificity of 90.6% and a positive predictive value of 6.1%. These values are higher than for any single screening instrument but still too low for a feasible and cost-effective screening strategy which might require longer follow-up intervals and application of additional instruments.

Prodromal Parkinson's disease as defined per MDS research criteria in the general elderly community

“…Indeed, population-based studies looking at single markers or combinations of a limited number of PD risk markers have reported low PPVs, on the order of a few percent, up to a maximum of 10%-25%. 9,10 Higher PPVs of 40% of risk markers have only been achieved in enriched cohorts with a high a priory risk for PD such as hyposmic individuals or AUC, area under the curve; FU, follow-up; LR, likelihood ratio; PD, Parkinson's disease; 95% CI, 95% confidence interval. As outlined by the MDS task force, 4 pretest probability for prodromal PD is based solely on estimated age-specific disease prevalence.…”

Frequency and profile of Parkinson's disease prodromi in patients with malignant melanoma

“…Olfaction testing was performed using the 12-item smell identification test from Sniffin’ Sticks (SS-12; Burghart Messtechnik, Wedel, Germany) 21. Hyposmia was considered to be present if less than 9 of 12 smells were correctly identified 14 21. Colour vision was assessed using the Farnsworth-Munsell 100-Hue test (Torso-Verlag e.K., Wertheim, Germany); age-related 95% percentiles of error scores obtained in a normal population were used as a cut-off value for indicating disturbed colour vision 22.…”

Potential sex differences in nonmotor symptoms in early drug-naive Parkinson disease

“…Because few of these symptoms are specific to PD, such research may require simultaneous measurements of multiple NMS in large prospective studies and lengthy follow-up. While such research efforts are currently under way, for example, in the Prospective Evaluation of Risk Factors for Idiopathic Parkinson's Syndrome Study 39 and the Parkinson At-Risk Syndrome Study, 40 careful examinations on NMS among patients with de novo PD may be a costeffective approach to search for specific NMS or combinations of NMS that can best differentiate patients with PD from controls. Our regression analysis showed that only a few NMS measures in combination could effectively differentiate patients with PD from controls.…”